Brief: BioArctic Says Rolling sBLA Initiated To The U.S. FDA For Leqembi As Subcutaneous Starting Dose For Treatment Of Early Alzheimer's Disease Under Fast Track Status

BioArctic AB

03/09/2025 24:33

Sept 2 (Reuters) - BioArctic AB BIOAb.ST:

ROLLING SBLA INITIATED TO THE U.S. FDA FOR LEQEMBI® IQLIK™ (LECANEMAB-IRMB) AS A SUBCUTANEOUS STARTING DOSE FOR THE TREATMENT OF EARLY ALZHEIMER'S DISEASE UNDER FAST TRACK STATUS

Source text: ID:nWkr3hJxhV

Further company coverage: [BIOAb.ST]

 ((Reuters.Briefs@thomsonreuters.com;))